Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director · Chief Technology Officer | August 28, 2018 | August 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date August 28, 2018 · Filed August 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBennett Limited | 1,041,054 |
Reported balance
After 2018-08-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-08-28 · Sale · Disposed 4,334 · Balance 1,041,054 F1: On August 28, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Bennett Limited, Bennett Limited sold 4,334 shares in multiple trades at prices ranging from $40.00 to $40.65. The price reported above reflects the weighted average sale price. Bennett Limited hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F2: Professor Palti shares voting and investment power for the shares held by Bennett Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 28, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Bennett Limited, Bennett Limited sold 4,334 shares in multiple trades at prices ranging from $40.00 to $40.65. The price reported above reflects the weighted average sale price. Bennett Limited hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: Professor Palti shares voting and investment power for the shares held by Bennett Limited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2017 Filed May 17, 2017 16:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $12.19 | $48,756.00 |
DisclosureSEC source: 0001209191-17-033045 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,825 F1 · price: On May 15, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.85 to $12.35. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2017 Filed May 15, 2017 16:45 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.69 | $46,772.00 |
DisclosureSEC source: 0001209191-17-032358 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,825 F2 · price: On May 12, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.55 to $11.80. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2017 Filed May 15, 2017 16:45 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.88 | $47,508.00 |
DisclosureSEC source: 0001209191-17-032358 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,825 F1 · price: On May 11, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.70 to $12.15. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2017 Filed May 11, 2017 16:04 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $12.25 | $48,992.00 |
DisclosureSEC source: 0001209191-17-031517 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,825 F2 · price: On May 10, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $12.10 to $12.45. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2017 Filed May 11, 2017 16:04 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $12.33 | $49,308.00 |
DisclosureSEC source: 0001209191-17-031517 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,825 F1 · price: On May 9, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $12.10 to $12.50. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 08, 2017 Filed May 9, 2017 16:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $12.09 | $48,376.00 |
DisclosureSEC source: 0001209191-17-030904 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,825 F2 · price: On May 8, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.775 to $12.50. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2017 Filed May 9, 2017 16:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.55 | $46,200.00 |
DisclosureSEC source: 0001209191-17-030904 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,825 F1 · price: On May 5, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.20 to $11.825. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.29 | $45,144.00 |
DisclosureSEC source: 0000899243-17-011976 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,825 F2 · price: On May 4, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.15 to $11.45. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2017 Filed May 5, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.55 | $46,216.00 |
DisclosureSEC source: 0000899243-17-011976 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,825 F1 · price: On May 3, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.10 to $11.85. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2017 Filed May 3, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.84 | $47,344.00 |
DisclosureSEC source: 0000899243-17-011613 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,825 F2 · price: On May 2, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.725 to $11.950. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.44 | $45,776.00 |
DisclosureSEC source: 0000899243-17-011613 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,825 F1 · price: On May 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.20 to $11.80. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 28, 2017 Filed May 1, 2017 16:07 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.29 | $45,160.00 |
DisclosureSEC source: 0000899243-17-011267 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,825 F2 · price: On April 28, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.65 to $11.60. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2017 Filed May 1, 2017 16:07 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.21 | $44,820.00 |
DisclosureSEC source: 0000899243-17-011267 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,825 F1 · price: On April 27, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.70 to $11.60. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $10.78 | $43,100.00 |
DisclosureSEC source: 0000899243-17-011007 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,825 F2 · price: On April 26, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.65 to $10.95. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $10.79 | $43,164.00 |
DisclosureSEC source: 0000899243-17-011007 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,825 F1 · price: On April 25, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.65 to $10.95. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.06 | $44,244.00 |
DisclosureSEC source: 0000899243-17-010851 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,825 F2 · price: On April 24, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.65 to $11.60. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.45 | $45,804.00 |
DisclosureSEC source: 0000899243-17-010851 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,825 F1 · price: On April 21, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.35 to $11.55. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.46 | $45,820.00 |
DisclosureSEC source: 0000899243-17-010709 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,825 F2 · price: On April 20, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $11.15 to $11.55. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 16:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $11.03 | $44,132.00 |
DisclosureSEC source: 0000899243-17-010709 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,825 F1 · price: On April 19, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.90 to $11.20. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $10.64 | $42,556.00 |
DisclosureSEC source: 0000899243-17-010524 · doc4.xml · nonDerivative · entry 4 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,825 F4 · price: On April 18, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.475 to $10.825. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $10.77 | $43,076.00 |
DisclosureSEC source: 0000899243-17-010524 · doc4.xml · nonDerivative · entry 3 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,825 F3 · price: On April 17, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.55 to $11.15. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2017 Filed Apr 19, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $10.43 | $41,724.00 |
DisclosureSEC source: 0000899243-17-010524 · doc4.xml · nonDerivative · entry 2 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,825 F2 · price: On April 13, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.30 to $10.65. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| April 12, 2017 Filed Apr 19, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,000 | $10.72 | $42,864.00 |
DisclosureSEC source: 0000899243-17-010524 · doc4.xml · nonDerivative · entry 1 Palti Yoram · CIK 0001654403 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,825 F1 · price: On April 12, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.40 to $11.05. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.